What are the oral medication options for post-stroke neuropathic pain?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Oral medication options for post-stroke neuropathic pain include anticonvulsants, tricyclic antidepressants, and SNRIs.

First-line treatment options

  • Amitriptyline is a reasonable first-line pharmacological treatment 1
  • Gabapentin or pregabalin can be used as first-line treatment for central post-stroke pain (CPSP) 1
  • Lamotrigine is also a reasonable first-line pharmacological treatment 1

Second-line treatment options

  • Duloxetine, an SNRI, can be used as second-line treatment 1
  • Pregabalin, gabapentin, carbamazepine, or phenytoin may be considered as second-line treatments 1

Additional considerations

  • Opioids or tramadol can be used for patients resistant to first and second-line treatment, but with caution due to the risk of physical dependency 1
  • Treatment should be individualized to the patient’s needs and response to therapy, and any side effects 1

From the Research

Oral Medication Options for Post-Stroke Neuropathic Pain

The following oral medications have been studied for the treatment of post-stroke neuropathic pain:

  • Amitriptyline: proven to be effective in the treatment of central post-stroke pain (CPSP) in a placebo-controlled study 2, 3
  • Lamotrigine: shown to be effective in reducing median pain score in patients with CPSP, with a dose of 200 mg/d being the most effective 3
  • Gabapentin: reported to control CPSP in a few patients, and may be an effective medication for the treatment of central post-stroke pain syndrome 2, 4
  • Gabapentinoids: recommended as first-line pharmacotherapy options for central post-stroke pain 5
  • Duloxetine: shown to be effective in reducing pain severity in CPSP patients, with 70.3% of patients showing at least 30% reduction of Numeric Rating Scale (NRS) scores compared with baseline at the third week 6

Considerations for Treatment

When considering treatment options for post-stroke neuropathic pain, it is essential to evaluate the efficacy and safety profile of each medication. For example:

  • Amitriptyline and lamotrigine have been shown to be effective in placebo-controlled studies, but may have side effects such as those associated with tricyclic antidepressants 2, 3
  • Gabapentin and gabapentinoids may be effective for some patients, but their efficacy and safety profile may vary 2, 5, 4
  • Duloxetine has been shown to be effective in reducing pain severity in CPSP patients, but may have side effects such as nausea, agitation, and somnolence 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pharmacologic treatment of central post-stroke pain.

The Clinical journal of pain, 2006

Research

Central post-stroke pain syndrome: yet another use for gabapentin?

American journal of physical medicine & rehabilitation, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.